Long-term ablation of DMH GLP-1R resulted in hyperphagia and obesity, and blunted exendin-4-induced anorexigenic metabolic effects [68,73]
As fat stores decrease, body measurements change across multiple regions
GLP-1 Agonists Show Promise in Treating Substance Use Disorders Nov 7, 2025 5 min read Updated: Dec 17, 2025 In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditionssuch as semaglutide and liraglutideare showing promise in treating substance use disorders (SUDs)
It's a ceiling
We found positive correlations between MTP mRNA and chylomicron fraction cholesterol and apo B48 [81]
Rodkey was appointed medical director to establish and develop a new pediatric emergency department at the Cleveland Clinic, and served for 10 years